JP2013526837A5 - - Google Patents

Download PDF

Info

Publication number
JP2013526837A5
JP2013526837A5 JP2012539021A JP2012539021A JP2013526837A5 JP 2013526837 A5 JP2013526837 A5 JP 2013526837A5 JP 2012539021 A JP2012539021 A JP 2012539021A JP 2012539021 A JP2012539021 A JP 2012539021A JP 2013526837 A5 JP2013526837 A5 JP 2013526837A5
Authority
JP
Japan
Prior art keywords
recombinant listeria
listeria strain
her2
pharmaceutical composition
neu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012539021A
Other languages
English (en)
Japanese (ja)
Other versions
JP5985397B2 (ja
JP2013526837A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/056534 external-priority patent/WO2011060260A2/en
Publication of JP2013526837A publication Critical patent/JP2013526837A/ja
Publication of JP2013526837A5 publication Critical patent/JP2013526837A5/ja
Application granted granted Critical
Publication of JP5985397B2 publication Critical patent/JP5985397B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012539021A 2009-11-11 2010-11-12 組換えリステリア株およびそれを含む免疫原性組成物 Expired - Fee Related JP5985397B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26027709P 2009-11-11 2009-11-11
PCT/US2010/056534 WO2011060260A2 (en) 2009-11-11 2010-11-12 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016152578A Division JP6329211B2 (ja) 2016-08-03 2016-08-03 脳腫瘍または乳腺腫瘍の発症を遅延させるための医薬の製造における組換えリステリア株の使用

Publications (3)

Publication Number Publication Date
JP2013526837A JP2013526837A (ja) 2013-06-27
JP2013526837A5 true JP2013526837A5 (enExample) 2013-12-26
JP5985397B2 JP5985397B2 (ja) 2016-09-06

Family

ID=43992418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012539021A Expired - Fee Related JP5985397B2 (ja) 2009-11-11 2010-11-12 組換えリステリア株およびそれを含む免疫原性組成物

Country Status (4)

Country Link
US (1) US9084747B2 (enExample)
EP (1) EP2498808A4 (enExample)
JP (1) JP5985397B2 (enExample)
WO (1) WO2011060260A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2011060260A2 (en) 2009-11-11 2011-05-19 Advaxis Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
US9040053B2 (en) * 2010-10-19 2015-05-26 Merial, Inc. Her2 DNA vaccine as adjunct treatment for cancers in companion animals
WO2012125551A1 (en) 2011-03-11 2012-09-20 Advaxis Listeria-based adjuvants
WO2013110030A2 (en) 2012-01-19 2013-07-25 Duke University Vaccines against antigens involved in therapy resistance and methods of using same
SG10201700392UA (en) * 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
EP3107566A4 (en) 2014-02-18 2017-10-11 Advaxis, Inc. Biomarker directed multi-target immunotherapy
CN103897067B (zh) * 2014-04-16 2016-04-13 中国医学科学院基础医学研究所 一种治疗肿瘤的重组多肽
SG11201608820WA (en) 2014-04-24 2016-11-29 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
JP2017514904A (ja) * 2014-05-02 2017-06-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｈｅｒ２陽性ガンの治療のための免疫療法および放射線療法の併用
WO2016007504A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of esr1 and methods of using the same
WO2016007499A1 (en) 2014-07-07 2016-01-14 Duke University Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same
WO2016011320A1 (en) * 2014-07-18 2016-01-21 Advaxis, Inc. Bivalent listeria-based delivery system of heterologous antigens
SG11201702857PA (en) * 2014-10-14 2017-05-30 Univ Pennsylvania Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
CN107847611A (zh) * 2015-05-26 2018-03-27 阿德瓦希斯公司 个性化的基于递送载体的免疫疗法及其用途
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
CN108697779B (zh) 2016-01-07 2023-09-19 杜克大学 癌症疫苗和递送方法
US11224665B2 (en) 2016-10-05 2022-01-18 Duke University Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same
US10487143B2 (en) 2016-10-05 2019-11-26 Duke University Vaccines against HER3 antigens and methods of using the same
CN110506107A (zh) 2016-11-30 2019-11-26 阿德瓦希斯公司 靶向复发性癌症突变的免疫原性组合物及其使用方法
US11179339B2 (en) 2017-09-19 2021-11-23 Advaxis, Inc. Compositions and methods for lyophilization of bacteria or listeria strains
ES3029080T3 (en) 2017-10-10 2025-06-23 Seattle Project Corp Neoantigen identification using hotspots
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
EP3762719A1 (en) 2018-03-09 2021-01-13 Advaxis, Inc. Compositions and methods for evaluating attenuation and infectivity of listeria strains
EP3785029A1 (en) 2018-04-27 2021-03-03 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
JP2023532444A (ja) 2020-06-23 2023-07-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド・ア・ボディ・コーポレイト 呼吸器病原体を診断し、ｃｏｖｉｄ－１９に関連する転帰を予測する方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US7662396B2 (en) * 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
EP0831854A4 (en) 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc OLIGONUCLEOTIDS WITH PHOSPHOROTHIOATE BINDINGS OF HIGH CHIRAL PURITY
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5922583A (en) * 1995-10-17 1999-07-13 Biostar Inc. Methods for production of recombinant plasmids
US6740506B2 (en) * 1995-12-07 2004-05-25 Diversa Corporation End selection in directed evolution
KR100574215B1 (ko) * 1997-04-17 2006-04-27 세키스이가가쿠 고교가부시키가이샤 도전성 미립자
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US7198920B1 (en) * 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
CA2486980A1 (en) 2002-05-29 2003-12-11 The Regents Of The University Of California Attenuated listeria spp. and methods for using the same
EP1408048A1 (en) 2002-10-07 2004-04-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vaccines of enhanced immunogenicity, and methods for preparing such vaccines
CA2512812A1 (en) * 2003-01-09 2004-07-29 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
DE10310261A1 (de) * 2003-03-05 2004-09-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Identifizierung von Antigen-Epitopen
EP1682173A4 (en) * 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINE ON LISTERIA BASE
US7855064B2 (en) * 2004-08-13 2010-12-21 The Trustees Of The University Of Pennsylvania Antibiotic resistance free vaccines and methods for constructing and using same
PT2942391T (pt) 2004-08-13 2018-10-09 Univ Pennsylvania Métodos de produção de vacinas não resistentes aos antibióticos
WO2007061848A2 (en) 2005-11-17 2007-05-31 The Trustees Of The University Of Pennsylvania Methods for producing, growing, and preserving listeria vaccine vectors
US20070207171A1 (en) * 2006-03-01 2007-09-06 Cerus Corporation Engineered listeria and methods of use thereof
US8268326B2 (en) * 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
EP2147092A4 (en) 2007-04-16 2010-06-09 Univ Pennsylvania ANTIBIOTIC RESISTANCE-FREE LISTERIA TRIBES AND METHOD OF CONSTRUCTING AND USING THEREOF
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
WO2011060260A2 (en) 2009-11-11 2011-05-19 Advaxis Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US20110223187A1 (en) * 2010-02-15 2011-09-15 Vafa Shahabi Live listeria-based vaccines for central nervous system therapy

Similar Documents

Publication Publication Date Title
JP2013526837A5 (enExample)
US12319727B2 (en) Exosome-targeted DNA vaccine
KR102409147B1 (ko) 종양분해성 백시니아 바이러스
ES2657168T3 (es) Composiciones que comprenden HMW-MAA y fragmentos de este para el tratamiento del cáncer
JP2017507943A5 (enExample)
KR20190082850A (ko) 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
US20190032064A1 (en) Personalized Delivery Vector-Based Immunotherapy and Uses Thereof
KR20180026670A (ko) 맞춤형 전달 벡터-기반의 면역 요법 및 이의 용도
JP2017513502A5 (enExample)
JP2014500724A5 (enExample)
JP6406647B2 (ja) 細胞性免疫誘導ワクチン
Lei et al. Cancer vaccines: platforms and current progress
CN106061995A (zh) Uspa2蛋白质构建体及其用途
JP2015511602A (ja) リステリアワクチン処理後のサプレッサー細胞機能抑制
KR20200070405A (ko) 암 관련 단백질로부터의 면역원성 불규칙변화성 펩타이드 및 그것의 사용 방법
KR20230004585A (ko) 개별화된 치료용 항암 백신
Bolhassani et al. Prospects and progress of Listeria-based cancer vaccines
Tadic et al. Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer?
Daemi et al. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model
Villegas-Mendez et al. In vivo delivery of antigens by adenovirus dodecahedron induces cellular and humoral immune responses to elicit antitumor immunity
WO2014129412A1 (ja) 免疫原性ポリペプチド表層発現ビフィズス菌
CN1650014A (zh) 用于治疗肿瘤的作为编码细胞抗原的核苷酸序列的载体的微生物
Bae et al. Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli
WO2018123507A1 (ja) 経口腫瘍ワクチンと免疫抑制阻害剤との併用によるがん治療
Umadevi et al. Vaccines: future prospects for oncogenic viral diseases